Pfizer Inc.

NYSE:PFE   3:59:57 PM EDT
+0.30 (+0.70%)
5:18:50 PM EDT: $43.10 -0.06 (-0.14%)

Pfizer And OPKO Announce Extension Of U.S. FDA Review Of Biologics License Application Of Somatrogon

Published: 09/24/2021 20:33 GMT
Pfizer Inc. (PFE) - Pfizer and Opko Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency.
Pfizer Inc - PDUFA Goal Date Has Been Extended by Three Months to January 2022, As a Result of Pfizer's Submission of Additional Data to Original Bla.